比较3种不同指南/共识评价极高风险或超高危动脉粥样硬化性心血管疾病危险分层和血脂达标率差异

来源 :中华内科杂志 | 被引量 : 0次 | 上传用户:qq20881010
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:探索3种不同标准对同一动脉粥样硬化性心血管疾病(ASCVD)队列极高风险或超高危的危险分层及低密度脂蛋白胆固醇(LDL-C)达标率的差异,并分析差异的主要来源。方法:连续入选2019年1—12月在首都医科大学附属北京安贞医院心内科行冠状动脉造影的ASCVD患者,分别应用2018美国胆固醇管理指南(简称2018指南)、2019中国胆固醇教育计划调脂治疗专家建议(简称2019建议)和2020超高危ASCVD患者血脂管理中国专家共识(简称2020共识)评估极高风险或超高危ASCVD患者比例,LDL-C绝对值达标率的差异,以及导致差异的来源。结果:研究共纳入患者1 864例,根据2018指南、2019建议、2020共识,极高风险或超高危ASCVD比例分别为59.4%、90.7%和65.6%;LDL-C绝对值达标率分别为37.2%、15.7%和13.7%,两两之间差异均有统计学意义(n P值均<0.001)。2020共识与2018指南达标率的差异61.5%缘于LDL-C目标值不同,38.5%缘于危险分层差异;2020共识与2019建议达标率的差异仅13.2%缘于LDL-C目标值不同,86.8%缘于危险分层差异。n 结论:3种极高风险或超高危ASCVD标准在同一队列中占比及LDL-C达标率差异显著。2020共识超高危人群比例适中,LDL-C达标率最低。2020共识与2018指南的差异主要缘于LDL-C目标值不同,与2019建议的差异主要缘于危险分层差异。“,”Objective:To explore the differences of risk stratification of very high-risk or extreme high-risk atherosclerotic cardiovascular diseases (ASCVD) and the attainment rates of low-density lipoprotein cholesterol (LDL-C) management targets evaluated by three different criteria, and the causal attributions of these differences.Methods:Patients with ASCVD were consecutively enrolled from January 1 to December 31 in 2019, and were evaluated for very high-risk or extreme high-risk and LDL-C goal attainment rates with 2018 American guideline on the management of blood cholesterol (2018AG), 2019 China Cholesterol Education Program (CCEP) Expert Advice for the management of dyslipidemias (2019EA) and 2020 Chinese expert consensus on lipid management of very high-risk ASCVD patients(2020EC), respectively. The causal attributions of the differences in attainment rates were analyzed as well.Results:A total of 1 864 ASCVD patients were included in this study. According to 2018AG, 2019EA and 2020EC, the proportions of the patients with very high-risk or extreme high-risk were 59.4%, 90.7%, and 65.6%, respectively. The absolute LDL-C target attainment rates were 37.2%, 15.7%, and 13.7%, respectively, the differences between each two rates were statistically significant (all n P<0.001). As to the differences in attainment rates between 2020EC and 2018AG, 61.5% were due to the different LDL-C goal attainment values and 38.5% were caused by the different risk stratifications, while for the differences between 2020EC and 2019EA attainment rates, different LDL-C goal attainment values were responsible for 13.2%, and different risk stratifications were responsible for 86.8% of the differences.n Conclusions:There are significant differences in the proportions and LDL-C attainment rates among the three different criteria for very high-risk or extreme high-risk ASCVD. 2020EC showed a moderate proportion of patients with extreme high-risk, and had the lowest LDL-C attainment rate. The differences between 2020EC and 2018AG are mainly due to the LDL-C target values, and the differences between 2020EC and 2019EA are mainly caused by the risk stratifications.
其他文献
唾液与血液、尿液等其他体液一样,内含物质极为丰富,其中唾液尿酸可以被检出。唾液尿酸与血清尿酸有良好的相关性,可以在一定程度上代替血清尿酸。近年来,国内外学者还发现唾液尿酸具有血清尿酸所不具备的独特的临床应用价值,其与青少年高血压、青少年体脂积累和子痫前期等的发生发展均有一定相关性,推测唾液尿酸具有一定的临床应用前景。本文综述近年国内外关于唾液尿酸的研究现状、临床应用价值及应用前景。“,”Saliva, like blood, urine, and other body fluids, contains e
目的:探讨梓醇对非酒精性脂肪肝病(non-alcoholic fatty liver disease, NAFLD)治疗及降脂机制。方法:高脂饮食喂养ICR小鼠8周以建立NAFLD体内模型,给予低剂量(50 mg/kg)、中剂量(150 mg/kg)、高剂量(300 mg/kg)剂量梓醇干预,分析小鼠体重、肝湿重、肝指数及生化指标。游离脂肪酸诱导人肝细胞LO2建立NAFLD细胞模型。实时荧光定量PCR检测脂肪酸合成相关基因水平。Western印迹法检测内质网应激(ERS)介导的蛋白激酶R样内质网激酶(PE
基于近年来新获取的临床研究证据,美国糖尿病学会颁布了2022年糖尿病诊疗标准。更新后的诊疗标准充分体现了以患者为中心、以改善临床预后为目标的糖尿病综合管理策略。本文针对该标准中关于降糖药物的选择、血压管理、血脂管理、抗血小板药物的应用以及合并心血管与肾脏疾病患者的降糖药物应用等方面的推荐建议进行简要介绍与评析。
法布雷病是一种多系统受累的罕见遗传溶酶体贮积症,及时进行特异性治疗可改善患者的临床症状,延缓疾病进展,从而延长患者预期寿命。目前,特异性治疗方法中酶替代治疗(ERT)和分子伴侣疗法已获得批准上市,底物减少疗法、新型ERT以及基因治疗等新型治疗方案正在临床研究中。本文基于《中国法布雷病诊疗专家共识(2021年版)》的治疗指导建议,并结合本科的治疗经验,总结了近年来关于法布雷病特异性治疗领域的新进展,重点阐述了特异性药物尤其是ERT的作用机制、临床获益、启动时机、疗效监测以及用药注意事项等。
论著/Original Article
期刊
成人斯蒂尔病是一种少见的全身性自身炎症性疾病。在我国,成人斯蒂尔病规范化诊疗的普及依然欠缺。中华医学会风湿病学分会查阅了该领域最新进展,在借鉴国内外诊治经验的基础上,制定了本规范,旨在规范成人斯蒂尔病的诊断,以减少误诊和漏诊,并对其治疗原则、方案予以建议,以减少不可逆损伤的发生,改善患者预后。“,”Adult-onset Still′s disease (AOSD) is a rare systemic autoinflammatory disorder. In China, standardized d
回顾性分析2019年至2021年于江苏省人民医院血液科接受艾曲泊帕联合环孢素A(CsA)的13例初治输血依赖非重型再生障碍性贫血(transfusion-dependent non-severe aplastic anemia,TD-NSAA)患者的临床资料,评估艾曲泊帕联合CsA治疗TD-NSAA的疗效、不良反应等。13例TD-NSAA患者治疗3个月总体血液学反应(OR)12/13。至随访截点,12例患者获得治疗反应,其中2例达完全血液学反应(CR),9例达部分血液学反应(PR),1例达血液学反应(HR
目的:探究影响非糖尿病个体β细胞去分化水平的潜在2型糖尿病风险因素。方法:通过胰岛素和β细胞去分化标志分子ALDH1A3免疫荧光染色法,检测38名非糖尿病和23例2型糖尿病患者胰腺切片中β细胞去分化水平。对非糖尿病个体胰岛β细胞去分化水平与年龄、体重指数、HbAn 1C、三酰甘油、总胆固醇等临床指标进行相关性分析。n 结果:与非糖尿病个体相比,2型糖尿病患者胰岛内ALDH1A3n +INSn +细胞比例明显升高(n P<0.001)。在糖尿病前期个体胰岛内A
原发性胆汁性胆管炎(primary biliary cholangitis,PBC)又名原发性胆汁性肝硬化,是一种由自身免疫介导,可进展为肝硬化的慢性肝内胆汁淤积性疾病,多见于中老年女性。而骨代谢障碍作为PBC患者的常见并发症,以骨质疏松症(osteoporosis,OP)最为突出。OP是指由多种原因导致,以骨密度和骨质量下降、骨微结构破坏、骨脆性增加、骨折风险增加为主要表现的全身性代谢性骨病。PBC患者并发OP导致骨折风险增加并严重影响患者生活质量,但目前其发病机制尚不明确且治疗方案尚不统一。因此,本文
目的:评价小檗碱对小鼠非酒精性脂肪性肝病程序性坏死的影响及其与腺苷酸活化蛋白激酶(AMPK)/转录活化因子6(STAT6)通路的关系。方法:将25只8周龄雄性C57BL/6N小鼠分为对照组、脂肪肝组、小檗碱治疗组(200 mg·kgn -1·dn -1)、AMPK抑制剂Compound C治疗组(0.2 mg·kgn -1·dn -1)、STAT6抑制剂AS1517499治疗组(10 mg·kgn -1·dn -1)。第12周末给小鼠称重并采集血